Astrazeneca PLC : American Depositary Shares Securities Litigation
On or around 01/27/2021 (Date of last review)
Filing Date: January 26, 2021
According to the Complaint, Astrazeneca PLC is a multinational biopharmaceutical company and was one of the early front-runners in the race to develop a COVID-19 vaccine. In April 2020, the Company partnered with Oxford University to develop a potential recombinant adenovirus vaccine for the virus, later dubbed AZD1222.
The Complaint alleges that Defendants misrepresented facts regarding the Company’s ongoing AZD1222 clinical trials and concealed problems that had arisen in the trials, including a dosing error which had been discovered early on by the Company but not disclosed to investors.
Please Log In or Sign Up to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.
When you sign up, you will have the option to save your search queries performed on the Advanced Search form.